Literature DB >> 24952689

Pre-capillary pulmonary hypertension and right ventricular dilation predict clinical outcome in cardiac resynchronization therapy.

Neal A Chatterjee1, Gaurav A Upadhyay2, Gaurav Singal2, Kimberly A Parks1, G William Dec1, Jagmeet P Singh2, Gregory D Lewis3.   

Abstract

OBJECTIVES: This study examined the prognostic significance of pre- and post-capillary components of pulmonary hypertension (PH) in patients receiving cardiac resynchronization therapy (CRT).
BACKGROUND: PH is common in patients with left ventricular systolic dysfunction (LVSD) receiving CRT. The impact of PH subtype on clinical outcome in CRT is unknown.
METHODS: The study population consisted of 101 patients (average age 66 ± 13 years, left ventricular ejection fraction 0.23 ± 0.07, and New York Heart Association functional class 3.2 ± 0.4) who underwent right heart catheterization in the 6 months before CRT. PH was defined as a mean pulmonary artery pressure ≥25 mm Hg; a significant pre-capillary contribution to elevated mean pulmonary artery pressure was defined as a transpulmonary gradient (TPG) ≥12 mm Hg. Clinical endpoints were assessed at 2 years and included all-cause mortality and a composite of death, left ventricular assist device, or cardiac transplantation.
RESULTS: Patients with TPG ≥12 mm Hg were more likely to experience all-cause mortality (hazard ratio [HR]: 3.2; 95% confidence interval [CI]: 1.3 to 7.4; p = 0.009) and the composite outcome (HR: 3.0; 95% CI: 1.4 to 6.3; p = 0.004) compared with patients with TPG <12 mm Hg. After multivariate adjustment for hemodynamic, clinical, and echocardiographic variables, only TPG ≥12 mm Hg and baseline right ventricular (RV) dilation (RV end-diastolic dimension >42 mm) were associated with the composite clinical outcome (p = 0.05 and p = 0.04, respectively).
CONCLUSIONS: High TPG PH and RV dilation are independent predictors of adverse outcomes in patients with LVSD who are receiving CRT. RV pulmonary vascular dysfunction may be a therapeutic target in select patients receiving CRT.
Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac resynchronization therapy; pulmonary hypertension; right ventricle

Mesh:

Year:  2014        PMID: 24952689     DOI: 10.1016/j.jchf.2014.02.004

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


  12 in total

Review 1.  Current role of echocardiography in cardiac resynchronization therapy.

Authors:  Donato Mele; Matteo Bertini; Michele Malagù; Marianna Nardozza; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

2.  Wall Thickness, Pulmonary Hypertension, and Diastolic Filling Abnormalities Predict Response to Postoperative Biventricular Pacing.

Authors:  Robin M Brusen; Rebecca Hahn; Santos E Cabreriza; Bin Cheng; Daniel Y Wang; Wanda Truong; Henry M Spotnitz
Journal:  J Cardiothorac Vasc Anesth       Date:  2015-02-07       Impact factor: 2.628

Review 3.  Cardiac Resynchronization Therapy-Emerging Therapeutic Approaches.

Authors:  Neal A Chatterjee; E Kevin Heist
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-06

4.  Relationship of soluble ST2 to pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy.

Authors:  Jonathan Beaudoin; Jackie Szymonifka; Zachary Lavender; Roderick C Deaño; Qing Zhou; James L Januzzi; Jagmeet P Singh; Quynh A Truong
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

5.  A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy.

Authors:  Minsi Cai; Wei Hua; Nixiao Zhang; Shengwen Yang; Yiran Hu; Min Gu; Hongxia Niu; Shu Zhang
Journal:  BMC Cardiovasc Disord       Date:  2020-05-13       Impact factor: 2.298

6.  Echocardiographic Assessment of Right Ventriculo-arterial Coupling: Clinical Correlates and Prognostic Impact in Heart Failure Patients Undergoing Cardiac Resynchronization Therapy.

Authors:  Bruno Bragança; Maria Trêpa; Raquel Santos; Inês Silveira; Marta Fontes-Oliveira; Maria João Sousa; Hipólito Reis; Severo Torres; Mário Santos
Journal:  J Cardiovasc Imaging       Date:  2020-01-21

7.  Detrimental effects of elevated transpulmonary gradient on outcomes following restrictive mitral annuloplasty in patients with pre-existing pulmonary hypertension.

Authors:  Satoshi Kainuma; Koichi Toda; Shigeru Miyagawa; Yasushi Yoshikawa; Hiroki Hata; Daisuke Yoshioka; Takuji Kawamura; Ai Kawamura; Noriyuki Kashiyama; Takayoshi Ueno; Toru Kuratani; Toshihiro Funatsu; Haruhiko Kondoh; Takafumi Masai; Arudo Hiraoka; Taichi Sakaguchi; Hidenori Yoshitaka; Takashi Daimon; Kazuhiro Taniguchi; Yoshiki Sawa
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

8.  Ratio between Right Ventricular Longitudinal Strain and Pulmonary Arterial Systolic Pressure: Novel Prognostic Parameter in Patients Undergoing Cardiac Resynchronization Therapy.

Authors:  Silvia Deaconu; Alexandru Deaconu; Alina Scarlatescu; Ioana Petre; Sebastian Onciul; Aura Vijiiac; Diana Zamfir; Gabriela Marascu; Corneliu Iorgulescu; Andrei Dan Radu; Stefan Bogdan; Radu Vatasescu
Journal:  J Clin Med       Date:  2021-05-31       Impact factor: 4.241

9.  Prognostic Value of Pulmonary Vascular Resistance by Magnetic Resonance in Systolic Heart Failure.

Authors:  Óscar Fabregat-Andrés; Jordi Estornell-Erill; Francisco Ridocci-Soriano; José Leandro Pérez-Boscá; Pilar García-González; Rafael Payá-Serrano; Salvador Morell; Julio Cortijo
Journal:  Arq Bras Cardiol       Date:  2016-02-02       Impact factor: 2.000

10.  Electro-echocardiographic Indices to Predict Cardiac Resynchronization Therapy Non-response on Non-ischemic Cardiomyopathy.

Authors:  Ziqing Yu; Xueying Chen; Fei Han; Shengmei Qin; Minghui Li; Yuan Wu; Yangang Su; Junbo Ge
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.